ArticleUlusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES2024
Is there a renal protective role for gelsolin treatment in crush syndrome? An experimental study.
Article in Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to investigate the impact of combining crush fluid resuscitation with gelsolin treatment on renal function in a rat model of crush syndrome.
methodsTwenty-four adult female Wistar albino rats were randomly assigned to one of three groups for crush syndrome treat-ment: Control (C) group, gelsolin + crush fluid (gel) group, and crush fluid only (CF) group, each containing eight rats. Sedated rats underwent unilateral hind limb compression of 2 kg using a compression device, maintained for five hours. The control group received no treatment post-compression. After removing the tourniquet, rats in the gelsolin group received an intravenous administration of recombinant human gelsolin at a dose of 2 mg/kg in 0.1 ml sterile saline, along with crush fluid. The CF group received only the crush solution.
resultsAt 24 hours, creatine kinase (CK) levels in the CF group were lower compared to those in the control and gelsolin + CF groups (132 IU vs. 630 IU [p=0.004] and 519.5 IU [p=0.014], respectively). By 48 hours, CK levels in both CF and gelsolin + CF groups were lower than in the control group (p<0.001 and p=0.014, respectively), with no significant difference between the CF and gelsolin + CF groups (p=0.773). At 72 hours, CK levels in the gelsolin + CF group were lower than in the control group (p=0.023) but comparable to the CF group (p>0.05). Blood urea nitrogen (BUN) levels at 24 and 72 hours were similar in the control and gelsolin + CF groups (p>0.05). At 48 hours, BUN levels in both CF and gelsolin + CF groups were lower than in the control group (p=0.001 and p=0.003, respectively), with no significant difference between the CF and Gelsolin + CF groups (p>0.05). At 24 hours, creatinine levels in the gelsolin + CF group were lower than in the control group (p=0.017), while levels in the CF and gelsolin + CF groups were similar (p>0.05). By 48 and 72 hours, creatinine levels in both CF and gelsolin + CF groups were similar but lower than in the control group (p<0.05). Changes in creatinine levels were comparable across all groups (p>0.05).
conclusionThis study marks the first instance in literature where it has been demonstrated that administering gelsolin along with crush solution does not yield superior results compared to crush solution alone in treating crush syndrome. Nonetheless, further research utilizing varying doses of gelsolin is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.